Plant-based Medicines
| Type | Bill |
|---|---|
| Session | 2022 Regular Session |
| Subjects |
Concerning establishing a policy review panel to study plant-based medicines to support mental health.
Bill Summary:
The bill creates the plant-based medicine policy review panel (policy review panel). The purpose of the policy review panel is to study the use of plant-based medicines to support mental health. The policy review panel operates for one year. The policy review panel shall submit a report on its findings and policy recommendations to the house of representatives public and behavioral health and human services committee and the senate health and human services committee, or any successor committees; the governor; and the department of human services.
The bill defines "plant-based medicine" as a naturally occurring hallucinogenic plant-based compound. Forms of plant-based medicine only include psilocybin, psilocyn, dimethyltryptamine, and ibogaine.
(Note: This summary applies to this bill as introduced.)
Committees
Related Documents & Information
| Date | Version | Documents |
|---|---|---|
| 01/21/2022 | Introduced |
| Date | Version | Documents |
|---|---|---|
| 04/05/2022 | FN1 |
| Activity | Vote | Documents |
|---|---|---|
| Postpone House Bill 22-1116 indefinitely. | The motion passed on a vote of 11-0. | Vote summary |
| Date | Location | Action |
|---|---|---|
| 04/05/2022 | House | House Committee on Public & Behavioral Health & Human Services Postpone Indefinitely |
| 01/21/2022 | House | Introduced In House - Assigned to Public & Behavioral Health & Human Services |